Neoadjuvant Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Single Center Study

Abstract

Abstract Objective:Aimed to evaluate the effect and response from the adjuvant chemotherapy for locally advanced oral squamous cell carcinoma. Methods: Retrospectively collected 46 patients with local late oral squamous cell carcinoma admitted from 2017 to 2021. The patients were treated with TPF induction chemotherapy. All patients completed at least 2 cycle of TPF (PF) regimen (75 mg / m2 of docetaxel on day 1 + 75 mg / M2 of cisplatin on day 1 + 750 mg / m2 of 5-fluorouracil on days 1 ~ 5, one cycle every 21 days), The primary end-points were overall response rate, safety of therapy and overall survival were evaluated. Results: After two cycles of TPF treatment, patients continued receiving surgery followed by radiotherapy or chemotherapy, include 5 patients were received PF. The complete remission rate was 6.25% (2/32), and the objective remission rate was 71.88% (23/32). Most of the adverse factors of chemotherapy response are alleviated. The median follow-up time was 26 months, and the median OS was 25.51 ± 3.81 months. Conclusion: Neoadjuvant chemotherapy, such as TPF or PF, plays an important role in the comprehensive treatment of advanced OSCC and postoperative assessments of white blood cell can provide high-quality prognostic information.